Document Detail

Applying quantitative benefit-risk analysis to aid regulatory decision making in diagnostic imaging: methods, challenges, and opportunities.
MedLine Citation:
PMID:  25107866     Owner:  NLM     Status:  In-Data-Review    
RATIONALE AND OBJECTIVES: Health agencies making regulatory marketing-authorization decisions use qualitative and quantitative approaches to assess expected benefits and expected risks associated with medical interventions. There is, however, no universal standard approach that regulatory agencies consistently use to conduct benefit-risk assessment (BRA) for pharmaceuticals or medical devices, including for imaging technologies. Economics, health services research, and health outcomes research use quantitative approaches to elicit preferences of stakeholders, identify priorities, and model health conditions and health intervention effects.
MATERIALS AND METHODS: Challenges to BRA in medical devices are outlined, highlighting additional barriers in radiology. Three quantitative methods-multi-criteria decision analysis, health outcomes modeling and stated-choice survey-are assessed using criteria that are important in balancing benefits and risks of medical devices and imaging technologies.
RESULTS: To be useful in regulatory BRA, quantitative methods need to: aggregate multiple benefits and risks, incorporate qualitative considerations, account for uncertainty, and make clear whose preferences/priorities are being used. Each quantitative method performs differently across these criteria and little is known about how BRA estimates and conclusions vary by approach. While no specific quantitative method is likely to be the strongest in all of the important areas, quantitative methods may have a place in BRA of medical devices and radiology.
DISCUSSION: Quantitative BRA approaches have been more widely applied in medicines, with fewer BRAs in devices. Despite substantial differences in characteristics of pharmaceuticals and devices, BRA methods may be as applicable to medical devices and imaging technologies as they are to pharmaceuticals. Further research to guide the development and selection of quantitative BRA methods for medical devices and imaging technologies is needed.
Maria Agapova; Emily Beth Devine; Brian W Bresnahan; Mitchell K Higashi; Louis P Garrison
Related Documents :
20383086 - An unexpected diagnosis: simulation reveals unanticipated deficiencies in resident phys...
25245656 - Scientific profile and professional responsibility of court-appointed medical technical...
16824536 - Natural sunlight and sun simulator photolysis studies of tetra- to hexa-brominated diph...
21791106 - Medication knowledge, certainty, and risk of errors in health care: a cross-sectional s...
9873846 - Assay of factor viii antigen (viii:cag) in 294 haemophilia a patients by a new commerci...
21279036 - Introducing the computer to family practice.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Academic radiology     Volume:  21     ISSN:  1878-4046     ISO Abbreviation:  Acad Radiol     Publication Date:  2014 Sep 
Date Detail:
Created Date:  2014-08-09     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9440159     Medline TA:  Acad Radiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1138-43     Citation Subset:  IM    
Copyright Information:
Copyright © 2014 AUR. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Including patient-reported outcomes and patient-reported resource-use questionnaires in studies.
Next Document:  Differentiation of lipoma from liposarcoma on MRI using texture and shape analysis.